文献速递前列腺癌

年轻男性主动监测/观察率上升及方案强化:基于全国商业健康保险理赔数据的回顾性队列研究

Rising Active Surveillance/Observation Rates and Regimen Intensification in Young Men: A Retrospective Cohort Study of National Commercial Health Insurance Claims Data.
PubMed 文献 · Urology · 2026-09-01

该研究基于2004至2023年Merative Marketscan商业保险数据库,回顾性分析≤65岁局限性前列腺癌男性,发现主动监测/观察(AS/O)比例从10.4%升至35.1%,前列腺切除术从55.5%降至42.8%。AS/O期间监测方案强度增加,1年后2年无治疗生存率为86.1%。

要点

  • ≤65岁局限性前列腺癌男性中AS/O使用率从10.4%上升至35.1%。
  • AS/O第一年内77.8%男性维持AS/O,2年无治疗生存率86.1%。
  • AS/O前2年泌尿科访视、活检、MRI和PSA监测均显著增加。

核心结论

  • 年轻男性中AS/O采用率增加且监测方案随时间强化,可能与指南落实或对功能保留的接受度提高有关。

研究设计与样本

  • 回顾性队列研究,纳入2004至2023年Merative Marketscan商业数据库中小于等于65岁、新诊断局限性前列腺癌且诊断前180天内有活检、至少2次评估管理访视的男性29484例,中位年龄58.0岁(IQR 55.0-61.0)。

主要发现

  • AS/O从10.4%升至35.1%,前列腺切除术从55.5%降至42.8%。
  • 诊断后第一年5861例(19.9%)接受AS/O,其中4561例(77.8%)维持AS/O。
  • AS/O1年后2年、3年、5年无治疗生存率分别为86.1%(95%CI 85.1%-87.0%)、79.0%(77.8%-80.2%)、68.8%(67.1%-70.4%)。
  • AS/O前2年内泌尿科访视从88.5%升至91.1%,活检从18.0%升至48.9%,MRI从0.0%升至63.7%,PSA从59.0%升至97.0%。

临床怎么用

  • 对于≤65岁局限性前列腺癌患者,可考虑提高AS/O的采用率并按照强化方案进行PSA、MRI和活检监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze active surveillance/observation (AS/O) trends, treatment selection, treatment-free survival, and surveillance regimen intensity in men ≤65 using a national commercial health insurance claims database. MATERIALS AND METHODS: We retrospectively reviewed the Merative Marketscan Commercial Database for localized prostate cancer among men ≤65 years between 2004 and 2023. Each had a newly-diagnosed prostate cancer, a biopsy <180 days before diagnosis, and ≥2 evaluation and management visits for prostate cancer. The primary outcomes were treatment selection and health services claims after diagnosis. Descriptive statistics and Kaplan-Meier analyses are reported. RESULTS: We identified 29,484 men ≤65 years with localized prostate cancer, with median age 58.0 years (IQR 55.0-61.0). AS/O increased from 10.4% to 35.1%, while prostatectomy decreased from 55.5% to 42.8%. Overall, 5861 (19.9%) men underwent AS/O in the first year after diagnosis; 4561 (77.8%) remained on AS/O. After 1 year of AS/O, treatment-free survival rates at 2-, 3-, and 5-years were 86.1% (95%CI:85.1%-87.0%), 79.0% (77.8%-80.2%), and 68.8% (67.1%-70.4%), respectively. In the first 2 years of AS/O, men who had a urologist visit rose from 88.5% to 91.1%, biopsy from 18.0% to 48.9%, MRI from 0.0% to 63.7%, and PSA from 59.0% to 97.0%. CONCLUSION: Younger men have increased adoption of AS/O and intensified AS/O regimens over time. These shifting treatment patterns could be due to improved guideline implementation or acceptance of AS/O to preserve functional status.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Mason JB, Hyman MJ, Sidana A, et al. Rising Active Surveillance/Observation Rates and Regimen Intensification in Young Men: A Retrospective Cohort Study of National Commercial Health Insurance Claims Data. Urology. 2026. PMID: 42679931. doi:10.1016/j.urology.2026.08.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。